FDA Refuses to Review Biohaven Drug for Rare Neuromuscular Disease With No Treatments

2023-07-27
临床3期临床2期
Biohaven acknowledges its experimental drug for spinocerebellar ataxia failed in a pivotal study, but the biotech hoped results showing benefit in a subgroup would be enough to secure approval for those patients given that this rare, inherited neuromuscular disorder has no approved therapies. The FDA disagrees. On Thursday, Biohaven said the FDA refused to review the application for the drug, troriluzole. Refuse to file letters are not public documents. According to Biohaven, the agency said the study’s failure to meet the primary endpoint “would not permit a substantive review.” The New Haven, Connecticut-based company said it plans to request a meeting to discuss the FDA’s concerns. Spinocerebellar ataxia (SCA) affects the cerebellum, the part of the brain that governs muscle control. The worsening of muscle control from SCA eventually leads to patients requiring wheelchairs. More than 40 types of this disease have been identified, many of them linked to a particular genetic mutation. Troriluzole doesn’t address the genetic mutation. Rather, it is intended to reduce levels of glutamate, a neurotransmitter whose dysfunction is associated with many neurological disorders, including SCA. Biohaven’s Phase 3 test of troriluzole evaluated the drug in all types of SCA. Last year, the company reported the drug failed to meet the main goal of showing, at week 48, a significant change in score according to a scale used to assess muscle control and movement. However, the company pointed to a post hoc analysis of the data showing a treatment effect in patients with SCA type 3, or SCA3. This type is the most common form of the disease and it represented 41% of the study population. The analysis showed SCA3 patients had fewer falls compared to those given a placebo, results the company said demonstrate clinically meaningful improvement. In May, Biohaven submitted a new drug application seeking approval of troriluzole for patients with SCA3. In a note sent to investors Thursday, William Blair analyst said the FDA’s decision to decline review of troriluzole was disappointing in light of other recent favorable regulatory decisions for rare disease drugs. As examples, he pointed to the approvals of Reata Pharmaceuticals drug Skyclarys for ultra rare disease Friedreich’s ataxia and Acadia Pharmaceuticals drug Daybue for Rett syndrome. Both drugs are the first approved treatments for their respective disease indications. Lugo said troriluzole may still have a path forward, but it is unlikely the FDA will change its decision without additional clinical data. That could mean Biohaven needs to conduct another Phase 3 study enrolling only SCA3 patients. Biohaven believes troriluzole’s mechanism of action has potential applications in other neurological diseases, but clinical trial results have been disappointing so far. In 2020, the drug failed a Phase 3 test in generalized anxiety disorder. In 2021, it failed a Phase 2/3 test in Alzheimer’s disease. Biohaven stands by the data produced for troriluzole in SCA. In a prepared statement, CEO Vlad Coric said that about 200 patients have been treated with the drug for up to three years and these patients have remained stable compared to the untreated natural history cohorts who showed disease progression over a similar time period. In addition to delaying disease progression, Coric said the troriluzole data also show a reduction in falls. “The risk-benefit profile for troriluzole warranted careful consideration by the FDA for this ultra-rare disorder,” Coric said. “SCA is clearly a severely debilitating, life-threatening disease with substantial unmet need. The approximately 6,000 patients in North America at least deserved a thorough review of the data package submitted.” Public domain image by Flickr user SciTechTrend
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。